{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ08867",
      "entity_text" : "infliximab ADAs",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "Vande Casteele et al [XREF_BIBR] also reported in 2013 that patients with sustained levels of infliximab ADAs were more likely to fail dose adjustment, with a likelihood ratio of 3.6 to fail dose escalation when antibodies to infliximab were> 9.1 U/mL (using HMSA).",
  "reading_complete" : "2020-08-08T19:38:12Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T19:34:12Z",
  "trigger" : "levels",
  "evidence" : [ "levels of infliximab ADAs" ],
  "pmc_id" : "5547373",
  "score" : 0
}